Evidence Review
Blood Pressure Reduction
The strongest evidence for OLE is in cardiovascular health. Perrinjaquet-Moccetti et al. (2008, PMID 18729245) conducted an open-label study in 40 borderline hypertensive monozygotic twins — pairs genetically identical — who were assigned to different doses of OLE (500 mg or 1000 mg/day of EFLA943 extract) or lifestyle advice only for 8 weeks. Mean systolic blood pressure differences between twin pairs were ≤6 mmHg (500 mg vs. lifestyle control) and ≤13 mmHg (1000 mg vs. 500 mg). LDL cholesterol was also significantly reduced. The twin design is particularly valuable here as it effectively controls for genetic confounding.
Susalit et al. (2011, PMID 21036583) conducted a randomized, double-blind, parallel, active-controlled trial in patients with stage-1 hypertension. Participants received either OLE (500 mg twice daily) or Captopril (12.5 mg twice daily) for 8 weeks. Both groups showed similar mean systolic blood pressure reductions (~11–13 mmHg) and diastolic reductions (~4–5 mmHg). OLE also produced a significant reduction in LDL cholesterol not seen with Captopril, while Captopril was not superior to OLE in blood pressure control. This head-to-head comparison is notably compelling.
Lockyer et al. (2017, PMID 26951205) ran a randomized, double-blind, placebo-controlled crossover trial in 60 pre-hypertensive males. Participants consumed OLE containing 136 mg oleuropein and 6 mg hydroxytyrosol daily for 6 weeks. Daytime systolic blood pressure was significantly reduced (p < 0.05), as were 24-hour systolic and diastolic readings. The crossover design with washout periods reduces confounding from individual variation.
Anti-Inflammatory Mechanisms
Qabaha et al. (2018, PMID 29099642) investigated which specific components of OLE were responsible for its anti-inflammatory activity. Using LPS-stimulated macrophages, they found that oleuropein at 20 μg/mL was the only OLE fraction demonstrating significant anti-inflammatory activity, while rutin, quercetin, and other isolated components showed no significant effect at comparable concentrations. This clarifies that standardizing to oleuropein content is pharmacologically relevant, not just a marketing claim.
Broad Pharmacological Review
Omar (2010, PMID 21179340) reviewed the emerging pharmacology of oleuropein across antioxidant, anti-inflammatory, anti-atherogenic, antimicrobial, antiviral, and metabolic domains. The review identified in vitro antiviral activity against HIV, influenza, herpes simplex (HSV-1), hepatitis C, and others — noting that HSV-1 replication was inhibited through PKR and transcription factor pathways. Antibacterial mechanisms involve disruption of peptidoglycan synthesis and cell membrane integrity, active against both gram-positive (Staphylococcus) and gram-negative (E. coli, Salmonella) organisms.
Limitations and Strength of Evidence
- Most antimicrobial evidence remains in vitro; robust human trials for infection outcomes are lacking.
- Blood pressure trials are relatively small (n = 40–60) and often of short duration (6–8 weeks).
- Long-term safety data beyond 8 weeks of supplementation in humans is limited.
- Standardization of OLE products varies widely; most clinical trials use proprietary extracts (EFLA943, Olivenol) not necessarily equivalent to commercial products.
Overall, the evidence for blood pressure reduction in pre-hypertensive and stage-1 hypertensive individuals is reasonably well-supported by multiple independent trials. The anti-inflammatory and antimicrobial properties are mechanistically credible but need more clinical trial confirmation. For cardiovascular benefit, OLE represents one of the better-evidenced botanical options with a consistent directional signal across studies.